

PRESCOS: YOUR PARTNER FOR PRECLINICAL R&D

Company Overview January 2011



PRESCOS
Preclinical Research &
Scientific Consulting Services



The PRESCOS Offering

- Introduction and Company Background
- The Service Offering
- PK and Pharmacology Services
- Advanced and Customized Statistical Solutions
- Summary

Introduction and Company Background



PRESCOS
Preclinical Research &
Scientific Consulting Services



PRESCOS: Quality Preclinical Contract and Expert Consulting Services

PRESCOS: Customized Planning, Execution and Analysis Solutions

- PRESCOS assists the pharmaceutical and biotechnology industries by offering quality contract research and expert consultancy services to its clients
- PRESCOS was founded out of the conviction that high quality preclinical pharmacology studies are essential for the efficient, economical and successful development of pharmaceutical drugs
- PRESCOS firmly believes that state-of-the-art quality solutions need to be applied to all stages of pharmacological studies, including the planning and conduct of studies, and the analysis of study results
- PRESCOS enables these requirements by applying “lessons learnt” from clinical studies to preclinical development



Company Background: The Management Team

PRESCOS Offers a Wealth of Expertise in Preclinical and Clinical Drug Development and Contract Research

- Joachim Vollmar, CEO - Co-founder of PRA International, a global Clinical Research Organization, and of ICDC, an independent Expert Consultancy. Brings 40+ years of experience in preclinical and clinical drug development with 100+ peer-reviewed scientific publications
- Thomas Moll, PhD, COO – Biotech R&D executive with 20+ years experience in basic and applied research and preclinical drug development . Extensive experience in the design and execution of IND enabling preclinical R&D programs, as well as individual pharmacology and safety studies



Company Background: Facilities and Staff

PRESCOS is Located in the Heart of San Diego's Biotech Area

- PRESCOS is located in the Torrey Pines area of San Diego, near major universities, research institutes, pharmaceutical and biotech companies
- The company's 5100 sf facility is located in a secure, controlled-access campus environment
- The PRESCOS facility comprises fully equipped mouse and rat vivarium spaces, procedure rooms, and analytical laboratories.





Company Background: Facilities and Staff – cont.

PRESCOS is Well Positioned to Offer Quality Contract Services

- Attending veterinarian is an active AAALAC council emeriti, and Senior Director of the Scripps Research Institute (SRI) Institutional Animal Program
- Capabilities include housing for immune competent and immune compromised rodents
- All animals are housed in microisolator cage systems
- Well-trained and experienced staff



The Service Offering



PRESCOS
Preclinical Research &
Scientific Consulting Services



PRESCOS: A Preclinical CRO and Expert Consultancy Service

PRESCOS Offers Customized Solutions for your R&D Outsourcing Needs

■ Pharmacology Services

- Pre-clinical in vivo and in vitro pharmacology studies
- Planning, execution, and analysis of single experimental studies as well as of comprehensive pharmacology programs

■ Consulting Services

- Pre-clinical in vivo and in vitro pharmacology study design and analysis
- Study and program evaluations, including technical and scientific due diligences
- Preparation of IND enabling R&D development plans, taking leads from discovery to the IND





Quality Track for Customized Solutions

Fully Integrated Planning, Conduct, Analysis and Reporting Processes

- Detailed planning meetings with client to determine client's needs, and to develop optimized study protocols
- Use of advanced statistical tools for study protocol generation and study initiation (e.g. cutting edge power analysis / sample size determination, state-of-the-art randomization procedures including stratification variables)
- Continuous communication during ongoing studies
- Established QC and QA procedures
- Comprehensive and integrated data management and analysis solutions using DMARS, the PRESCOS proprietary data management, analysis and randomization system
- On-time delivery of study reports





Drug Screening and Evaluation

PRESCOS Offers Rodent PK Studies as well as Rodent In Vitro and In Vivo Pharmacology Models of Disease

■ Rat and Mouse PK studies

- Single dose PK studies
- Repeat dose PK studies

■ In vitro pharmacological studies

- Cell proliferation and toxicity assays
- Human cancer cell models

■ In vivo pharmacological studies

- Cancer models in immune compromised, irradiated and immune competent rodents
- Autoimmune disease models
- Asthma models (Airway Hyperreactivity Models)
- Inflammation models
- Additional models, including models for wound healing, alopecia areata, hepatic fibrosis (CCI4-induced in mice)





Routes of Administration

PRESCOS Offers the Following Routes of Administration:

- Oral (PO) administration
- Dermal (Dermal Patches, Topical Applications)
- Intravenous (IV)
- Subcutaneous (SC)
- Intradermal (ID)
- Intraperitoneal (IP)
- Intramuscular (IM)
- Intratracheal (IT)
- Intranasal (IN)
- Continuous Infusion
- Intravitreous (in rats)



Terminal Procedures

PRESCOS Offers the Following Terminal Procedures:

- Whole blood, serum and plasma collection (also in-life)
- Cerebrospinal fluid collection
- Bone marrow collection
- Tissue and organ collection
- Harvesting of tumors
- Processing and preservation of collected fluids, cells, tissues and organs
- Ex vivo analytical services

PK and Pharmacology Services



PRESCOS
Preclinical Research &
Scientific Consulting Services



Pharmacokinetic Studies




Evaluation of Pharmacokinetic Parameters Following Single Dosing, Repeat Dosing or e.g. Timed Perfusion

- PK Studies in mice and rats
- Evaluation of biologics and small molecule drugs
- Conduct of GLP toxicology enabling studies
- Determination of serum PK parameters such as C_{max} , T_{max} , $T_{1/2}$, AUC and drug clearance
- Study protocols are custom developed on the basis of compound(s), route of administration, dosing regimen



Pharmacokinetics of Omeprazole After IV Administration in Male Wistar Rats

Plasma Omeprazole concentration after single IV bolus administration






Omeprazole	AUC* [µg h/ml]	T _{1/2} * [h]	T _{max} * [h]	C _{max} * [µg/ml]
IV 2.5 mg/kg	1.06/0.06	0.06/0.001	0.09/0.004	4.35/0.06
IV 5.0 mg/kg	1.88/0.16	0.05/0.008	0.07/0.01	10.8/0.16

* Numbers given are Mean/SEM



Pharmacokinetics of Omeprazole After PO Administration in Male Wistar Rats

Plasma Omeprazole concentration after single PO administration



Omeprazole	AUC* [µg h/mL]	T _{1/2} * [h]	T _{max} * [h]	C _{max} * [µg/mL]
PO 2.5 mg/kg	1.00/0.066	0.14/0.018	0.23/0.033	1.77/0.25
PO 5.0 mg/kg	3.96/0.34	0.16/0.017	0.26/0.03	5.78/0.75

* Numbers given are Mean/SEM



In Vitro Cancer Models

In Vitro Assays to Help Determine the Efficacy, Mechanism of Action, and Toxicity of Compounds

- Cell proliferation and cellular toxicity assays
- Soft agar colony formation assay
- Apoptosis assays





In Vivo Cancer Models

In Vivo Cancer Models to Help Determine the Efficacy, Mechanism of Action, and Toxicity of Compounds

- Human cancer xenografts in immunodeficient (athymic nude, scid) mice
 - Breast (MDA-MB231, MDA-MB468, MCF-7, BT-474, SKBR3)
 - Prostate (PC-3, DU-145)
 - Lung (A549, H460, H146)
 - Stomach (N87)
 - Colon (Colo-205, DLD-1, HT29)
 - Liver (HepG2)
 - Pancreas (Mia-Paca, Panc1)
 - Leukemia (HL-60, Hut78, K562, Raji (Ramos))

- Tumor models in irradiated mice




In Vivo Cancer Models – cont.

In Vivo Cancer Models to Help Determine the Efficacy, Mechanism of Action, and Toxicity of Compounds

- Spontaneous and Syngeneic Tumors in Mice and Rats (e.g. for immunotherapeutics)
 - Mouse prostate (spontaneous; TRAMP mice)
 - Mouse melanoma (B16F10)
 - Mouse colon (CT26)
 - Mouse lung (M109)
 - Rat gliosarcoma (9L)

In Vivo Cancer Model: Example of a Study Design




Live challenge: 5×10^5 M109 cells, s.c.
Treatments delivered i.p.

<u>Gp</u>	<u>Treatment regimen</u>
A	Vehicle control (DMSO 1:10 in PBS), qd \times 7
B	16 mg/kg compound X, qd \times 7
C	8 mg/kg compound X, qd \times 7
D	4 mg/kg compound X, qd \times 7




Drug Treatment Limits The Growth of M109 Lung Carcinoma During Therapy





Drug Treatment is Toxic and Leads to Dose Dependent Animal Mortality





Autoimmune Disease Models

PRESCOS Offers Rodent Models for a Variety of Autoimmune Diseases

■ Rheumatoid Arthritis

- Collagen-Induced Arthritis (CIA) in mouse and rat
- Collagen Antibody Induced Arthritis (CAIA) in the mouse
- Streptococcal cell wall induced arthritis in the rat

■ Multiple Sclerosis

- Experimental autoimmune encephalomyelitis (EAE) models in mouse and rat, including
 - PLP-induced EAE in SJL/J mice
 - MOG-induced EAE in C57BL/6 mice
 - MBP-induced EAE in Lewis rats

■ Uveitis


- Mouse (C57BL/6) and rat (Lewis) uveitis using interphotoreceptor retinoid binding protein (IRBP) derived peptides for disease induction.



Autoimmune Disease Models – cont.

- **Systemic Lupus Erythematosus (SLE)**
 - Several mouse models of the disease are available at PRESCOS. These include the MRL/lpr mouse model, as well the NZW and/or NZW/NZB F1 mouse models of SLE
- **Diabetes**
 - Streptozotocin-induced diabetes in mice and rats
 - Diabetes in NOD mice
- **Idiopathic Pulmonary Fibrosis (IPF)**
 - Bleomycin-induced pulmonary fibrosis in mice (C57BL/6; or ICR)
- **Scleroderma**
 - Bleomycin-induced dermal scleroderma
 - Murine sclerodermatous graft versus host disease (skin and lung fibrosis)
- **Primary Biliary Cirrhosis (PBC)**
 - PBC model in NOD.c3c4 mice

Collagen-Induced Arthritis in Mice: Example of a Study Design







CIA: Example of Disease Scoring and Disease Progression

Mouse:	1	2	3	4	5	6	7	8
Treatment:	Cnt	Cnt	Cnt	Cnt	Trt	Trt	Trt	Trt
Day 1:	1 1 0 0	0 0 1 1	1 0 0 0	0 0 0 1	0 0 0 1	0 0 0 1	0 0 0 1	0 0 0 1
Day 2:	2 2 0 0	0 0 2 2	2 0 1 0	0 0 0 1	0 0 0 1	0 0 0 1	0 0 1 1	0 0 1 1
Day 3:	3 3 0 2	0 0 2 2	2 0 1 0	0 0 0 1	0 0 0 1	0 0 0 1	0 0 1 1	0 0 1 1
Day 4:	3 3 1 3	0 0 2 2	3 0 1 0	0 0 0 1	0 0 0 1	0 0 2 1	0 0 1 1	0 0 2 1
Day 5:	3 3 1 3	0 0 3 2	3 0 1 0	0 0 0 1	0 0 0 1	0 0 3 1	0 0 2 1	0 0 3 1
Day 6:	3 3 1 3	1 1 3 2	3 0 1 2	0 0 0 1	0 0 0 1	0 0 3 1	0 0 3 1	0 0 3 1
Day 7:	3 3 1 3	1 2 3 2	3 0 1 2	0 0 0 1	0 0 0 1	0 0 3 1	0 0 3 1	0 0 3 1
Day 8:	4 3 1 3	1 2 3 2	4 0 1 2	0 0 0 1	0 0 0 1	0 1 3 1	0 0 3 1	0 0 3 1
Day 9:	4 4 1 3	0 3 3 2	4 0 1 3	0 0 0 1	0 0 0 1	0 1 3 1	0 0 3 1	0 0 3 1
Day 10:	4 4 1 3	0 3 3 2	4 0 2 3	0 0 0 0	0 0 0 1	0 2 3 1	0 0 3 1	0 0 4 1
Day 11:	4 4 1 3	0 3 3 2	4 1 2 4	0 0 0 0	0 0 0 1	0 3 4 1	0 0 4 1	0 0 4 0
Day 12:	4 4 1 3	0 4 3 2	4 1 2 4	0 0 0 0	0 0 0 1	0 4 4 1	0 0 4 1	0 0 4 0

CIA: Histopathology and Pathological Scoring



Ferrari-Lacraz et al. (2004) JI, 173:5818




CIA: Gene Expression Analysis


Clinical Scores (on a scale from 0 to 4 per limb):

0 0 4 2 0 3 3 1 4 0 2 3 0 0 3 1


0 0 2 1 3 0 1 3




IL-1 β



IL-6



MMP3




GAPDH



EAE in Mice: Example of a Study Design





Immunize s.c. with PLP (200µg) in CFA
+ 100ng PT, i.v.





EAE: Monitoring of Disease





Inflammation and Asthma Models

PRESCOS Offers a Variety of Rodent Models of Inflammation, Including a Mouse Airway Hyperreactivity Asthma Model

- Asthma
 - Mouse ovalbumin-induced airway hyperreactivity model (AHR)
- Chronic Obstructive Pulmonary Disease (COPD)
 - Elastase-induced COPD
 - Smoke inhalation induced COPD
- Inflammatory Bowel Disease (IBD)
 - Dextran Sulfate (DSS) induced gastrointestinal inflammation
 - Oxazolone and Trinitrobenzene Sulfonic Acid (TNBS) induced colitis
- Bacterial antigen induced inflammatory responses in mice and rats
- Irritant-induced contact hypersensitivity (CHS) and delayed-type hypersensitivity (DTH) inflammation models
- Mouse airpouch model (leukocyte migration)




Allergen (OVA)-induced Airway Hyperreactivity in Mice: Example of a Study Design



Days 0 and 14: Immunize IP with OVA in Alum

Days 32, 33, and 34: IN challenge with OVA, vehicle




Control treatment (positive control)

Monitoring of overall health, survival, body weight

Terminal assays for lung histopathology, BALF cell counts, IgE

Customized treatment protocol with compound and controls

AHR: Leukocyte Counts in Bronchoalveolar Lavage Fluid



Naïve (n=11): Naïve mice, untreated; Control (n=11): Immunized with OVA
 Challenge (n=12): Immunized with OVA, challenged with OVA, treated with vehicle
 Treatment (n=12): Immunized with OVA, challenged with OVA, treated with dexamethasone

p values were calculated using a Welch-t-test. Similar results were obtained using a modified Wilcoxon test.




Elastase-Induced COPD in Mice: Example of a Study Design




Day 0: Intranasal administration of porcine pancreatic elastase

Customized treatment protocol with compound and controls



Terminal assays for lung histopathology, BALF cell counts

Elastase-Induced COPD: Leukocyte Counts in Bronchoalveolar Lavage Fluid (BALF)



Acute lung injury was induced by IN administration of elastase or saline (control) and BALF collected from one half of the lung after 1 day and after 7 days, respectively. Values given are mean \pm SEM.

Advanced and Customized Statistical Solutions



PRESCOS
Preclinical Research &
Scientific Consulting Services




Treatment of Mouse Thymoma (EL4) in Immuno-competent Mice

Inject mice with 5×10^5 EL4 cells (SC)
to establish tumor






Treat with X ug of negative control, positive control, test compound (SC) on
days 6, 13, 17 and 20 post tumor establishment





EL4 Thymoma is a Fast Growing Mouse Tumor






Statistical Evaluation: Limitations of Study Case

PRESCOS Offers Model-Driven and Customized Statistical Analysis Solutions


- Due to physiological limitations and IACUC regulations tumor size is limited, potentially biasing study results at later time points (and/or animals with large tumor volumes)
- Standard t-test or ANOVA analyses do not allow an appropriate statistical evaluation over the study duration
- Many standard analysis programs do not determine confidence intervals

Statistical Evaluation: Limitations of Study Case – cont.



Time dependence of tumor volumes; experimental studies often show significant variability for individual data points

Statistical Evaluation: Limitations of Study Case – cont.



For background on statistical methodology see:
Hothorn (2006) DIJ, 40:229

AUC and baseline corrected AUC variance analysis incorporate data variance and allow inclusion of study endpoint (Day 24 analysis included)



Statistical Evaluation: Limitations of Study Case – cont.

Comparison	Eff in %	Two-sided confidence interval In %
Positive Control / Negative Control	75	[66; 85]
Treatment/ Negative Control	82	[70; 94]
Treatment/ Positive Control	108	[91; 128]

Efficacy estimates and their two-sided 95% confidence intervals for mortality adjusted AUC

For background on statistical methodology see:
Hothorn (2006) DIJ, 40:229

Summary



PRESCOS
Preclinical Research &
Scientific Consulting Services



PRESCOS: Quality and Science Driven Research and Preclinical Development Solutions

PRESCOS combines extensive expertise in preclinical pharmacology and statistics to offer quality custom solutions and expert consulting services to its clients:

- PRESCOS can offer support at all stages of preclinical research and development, and offers services at all scales, from individual compound test studies to comprehensive preclinical pharmacology programs
- PRESCOS also offers preclinical study design and analysis services, conducts study and program evaluations, including technical and scientific due diligences - and has the capability to prepare IND enabling R&D development plans, taking leads from discovery to IND filing



Thank you very much for your consideration, we very much look forward to working with you!